3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
9
Active not recruiting
8
Terminated
6
Not yet recruiting
2
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
3
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Interventions
Drug Therapy
107
Cisplatin
97
Radiotherapy
89
Carboplatin
87
Bevacizumab
79
Oxaliplatin
74
tislelizumab
68
Capecitabine
68
Gemcitabine
64
Cyclophosphamide
64
toripalimab
62
Paclitaxel
57
pembrolizumab
55
sintilimab
53
Specimen Handling
53
Surgical Procedures, Operative
52
anlotinib
49
Fluorouracil
49
Magnetic Resonance Spectroscopy
48
Immune Checkpoint Inhibitors
43
Blood Specimen Collection
42
130-nm albumin-bound paclitaxel
42
Standard of Care
38
camrelizumab
36
fludarabine
35
lenvatinib
34
Leucovorin
34
venetoclax
30
Radiosurgery
30
Immunotherapy
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
OTHER
×
belantamab mafodotin
×
Clear all
NCT07285239
2026-05-18
PrE1005
PrECOG, LLC.
Phase 3
Not yet recruiting
500 enrolled
NCT05874193
2026-02-05
COSTA
Duke University
Phase 2
Not yet recruiting
33 enrolled